NDAORALSUSPENSIONPriority Review
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
HETLIOZ LQ (tasimelteon) by Vanda Pharmaceuticals is melatonin receptor agonists [moa]. Approved for non-24-hour sleep-wake disorder. First approved in 2020.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HETLIOZ LQ is an oral suspension formulation of tasimelteon, a melatonin receptor agonist approved in December 2020 for treating circadian rhythm sleep disorders including Non-24-Hour Sleep-Wake Disorder and conditions like Smith-Magenis Syndrome and Autism Spectrum Disorder. The drug works by selectively binding to melatonin receptors to help regulate sleep-wake cycles in patients with disrupted circadian rhythms.
$0.843MPart D
Peak14.8 years to LOEThe product is in peak commercial phase with minimal Part D spending ($843K in 2023), suggesting either niche market penetration or significant growth opportunity for commercial expansion teams.
Mechanism of Action
Melatonin Receptor Agonists
Pharmacologic Class:
Melatonin Receptor Agonist
Indications (1)
Clinical Trials (20)
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
Started Apr 2025
420 enrolled
Insomnia Disorder
Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant
Started Oct 2024
60 enrolled
Sleep Wake DisordersSleep Disorders, Circadian RhythmChronobiology Disorders+1 more
The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)
Started Sep 2023
20 enrolled
REM Behavior Disorder
Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers
Started May 2022
36 enrolled
Healthy
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
Started Jul 2021
100 enrolled
Autism Spectrum DisorderSleep DisorderNeurological Disorder+1 more
Worked on HETLIOZ LQ at Vanda Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.